Feed items
Websites advertising cholesterol-lowering drugs of poor quality
Submitted by Correspondent on Fri, 02/03/2012 - 03:30A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
AstraZeneca fourth quarter and full year results 2011
Submitted by Correspondent on Thu, 02/02/2012 - 13:30AstraZeneca's revenue in the fourth quarter was unchanged at CER and on an actual basis as exchange rate movements were neutral to reported revenue. Adjusted for the disposal of Astra Tech, revenue growth was 2 percent.
Protein structures give disease clues
Submitted by Correspondent on Thu, 02/02/2012 - 03:30Using some of the most powerful nuclear magnetic resonance equipment available, researchers at the University of California, Davis, are making discoveries about the shape and structure of biological molecules - potentially leading to new ways to treat or prevent diseases such as breast cancer and Alzheimer's disease.
Pfizer reports fourth-quarter and full-year 2011 results
Submitted by Correspondent on Wed, 02/01/2012 - 03:30Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2011. Fourth-quarter 2011 revenues were $16.7 billion, a decrease of 4% compared with $17.4 billion in the year-ago quarter, which reflects an operational decline of $765 million, or 5%, and the favorable impact of foreign exchange of $157 million, or 1%.
Novartis extends commitment to help achieve final elimination of leprosy
Submitted by Correspondent on Tue, 01/31/2012 - 03:30Novartis will continue its work with the World Health Organization (WHO) toward a world free of leprosy by extending its drug donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020.
Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion
Submitted by Correspondent on Mon, 01/30/2012 - 03:30Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.
Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care
Submitted by Correspondent on Mon, 01/30/2012 - 03:30Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer's Initiative introduced the Alzheimer's Challenge 2012 at the Care Innovations Summit in Washington, D.C.